Mobile telemedicine delivery significantly enhanced HCV treatment initiation for underserved rural populations.

Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...

Significant treatment gaps persist for pregnant individuals with HCV, leading to missed therapeutic opportunities and vertical transmission risks.

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...

When managing patients with hepatitis C virus (HCV), initiating treatment of the infection promptly is more important than determining the severity of their liver disease with the customary staging ...

This analysis demonstrates value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C in the US Kaiser Permanente health system. Objectives: Direct-acting antivirals ...

Please provide your email address to receive an email when new articles are posted on . The FDA’s recent authorization of a rapid, point-of-care test to diagnose current hepatitis C virus infection is ...

Hepatitis C and opioid use disorder are both chronic but treatable conditions. Yet many Americans living with this deadly combination aren’t offered treatment. Imagine going to your doctor with strep ...